Gergely Szakacs, Univ.-Prof. PhD
Koordinator Forschungsschwerpunkt "Sicherheit chemischer Substanzen und Krebsprävention"
Gruppenleiter
E-Mail: gergely.szakacs [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57619
Fax: +43 (0)1 40160 - 957616
Research Focus
Our research revolves around membrane transporters and drug resistant cancer. Based on our findings demonstrating the paradoxical sensitivity of cancer cells overexpressing the MDR exporter P-gp, our aim has been to exploit the collateral sensitivity of MDR cells (Chem. Rev. 114, 5753–5774 (2014)). Recently, our interests turned to therapy resistance mechanisms linked to drug tolerant persister cells (DTPs). We have adapted genetically engineered mouse models of cancer to study the evolution of resistance.
In 2020, we established a research consortium within the university, and successfully applied for funding from the FWF Doc-fund to establish an excellence-based graduate training program
(https://phd-ippto.meduniwien.ac.at/).
Videos
Selected Publications:
Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein-Expressing Cells
Cserepes M, Türk D, Tóth S, Pape VFS, Gaál A, Gera M, Szabó JE, Kucsma N, Várady G, Vér-tessy BG, Streli C, Szabó PT, Tovari J, Szoboszlai N, Szakács G.
Cancer Res. 2020 Feb 15;80(4):663-674. doi: 10.1158/0008-5472.CAN-19-1407.
Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines
Karai E, Szebényi K, Windt T, Fehér S, Szendi E, Dékay V, Vajdovich P, Szakács G, Füredi A.
Cancers (Basel). 2020 Apr 29;12(5). doi: 10.3390/cancers12051117.
Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line
Hámori L, Kudlik G, Szebényi K, Kucsma N, Szeder B, Póti Á, Uher F, Várady G, Szüts D, Tóvári J, Füredi A, Szakács G.
Int J Mol Sci. 2020 Feb 11;21(4). doi: 10.3390/ijms21041185.
In vivo characterization of [18F]AVT-011 as a radio-tracer for PET imaging of multidrug resistance
Kannan P, Füredi A, Dizdarevic S, Wanek T, Mairinger S, Collins J, Falls T, van Dam RM, Ma-heshwari D, Lee JT, Szakács G, Langer O.
Eur J Nucl Med Mol Imaging. 2019 Nov 15;. doi: 10.1007/s00259-019-04589-w.
Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer
Füredi A, Szebényi K, Tóth S, Cserepes M, Hámori L, Nagy V, Karai E, Vajdovich P, Imre T, Szabó P, Szüts D, Tóvári J, Szakács G.
J Control Release. 2017 Sep 10;261:287-296. doi: 10.1016/j.jconrel.2017.07.010.
Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity
Füredi A, Tóth S, Szebényi K, Pape VF, Türk D, Kucsma N, Cervenak L, Tóvári J, Szakács G.
Mol Cancer Ther. 2017 Jan;16(1):45-56. doi: 10.1158/1535-7163.MCT-16-0333-T.
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance
Szakács G, Hall MD, Gottesman MM, Boumendjel A, Kachadourian R, Day BJ, Baubichon-Cortay H, Di Pietro A.
Chem Rev. 2014 Jun 11;114(11):5753-74. doi: 10.1021/cr4006236.
Identification of compounds selectively killing multidrug-resistant cancer cells
Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, Szakács G.
Cancer Res. 2009 Nov 1;69(21):8293-301. doi: 10.1158/0008-5472.CAN-09-2422. Epub 2009 Oct 20.
Targeting multidrug resistance in cancer
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM.
Nat Rev Drug Discov. 2006 Mar;5(3):219-34. doi: 10.1038/nrd1984.
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells
Szakács G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM.
Cancer Cell. 2004 Aug;6(2):129-37. doi: 10.1016/j.ccr.2004.06.026.